Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

CARIS LIFE Aktie

 >CARIS LIFE Aktienkurs 
16.75 EUR    (TradegateBSX)
Ask: 16.8 EUR / 1800 Stück
Bid: 16.7 EUR / 700 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CARIS LIFE Aktie über LYNX handeln
>CARIS LIFE Performance
1 Woche: +18,0%
1 Monat: -0,3%
3 Monate: -27,2%
6 Monate: -37,5%
1 Jahr: 0%
laufendes Jahr: -29,6%
>CARIS LIFE Aktie
Name:  CARIS LIFE SCIENCES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1421521071 / A41A14
Symbol/ Ticker:  49J (Frankfurt) / CAI (NASDAQ)
Kürzel:  FRA:49J, ETR:49J, 49J:GR, NASDAQ:CAI
Index:  -
Webseite:  https://www.carislifescie..
Profil:  Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing..
>Volltext..
Marktkapitalisierung:  4683.08 Mio. EUR
Unternehmenswert:  4366.15 Mio. EUR
Umsatz:  703.48 Mio. EUR
EBITDA:  58.69 Mio. EUR
Nettogewinn:  -58.99 Mio. EUR
Gewinn je Aktie:  -1.66 EUR
Schulden:  370.51 Mio. EUR
Liquide Mittel:  691.14 Mio. EUR
Operativer Cashflow:  65.36 Mio. EUR
Bargeldquote:  6.29
Umsatzwachstum:  73.61%
Gewinnwachstum:  78.71%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CARIS LIFE
Letzte Datenerhebung:  06.04.26
>CARIS LIFE Kennzahlen
Aktien/ Unternehmen:
Aktien: 282.58 Mio. St.
Frei handelbar: 42.68%
Rückkaufquote: -12.86%
Mitarbeiter: 1846
Umsatz/Mitarb.: 0.38 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 70.74%
Bewertung:
KGV: -
KGV lG: 122.13
KUV: 6.38
KBV: 9.6
PEG-Ratio: -0.23
EV/EBITDA: 74.39
Rentabilität:
Bruttomarge: 66.4%
Gewinnmarge: -8.39%
Operative Marge: 5.56%
Managementeffizenz:
Gesamtkaprendite: -9.27%
Eigenkaprendite: -45.37%
>CARIS LIFE Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
02.04.26 - 14:33
 Caris Life Sciences Announces Launch of Caris ChromoSeq, the World′s First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies (PR Newswire)
 
Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight IRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio......
01.04.26 - 00:03
 Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect (PR Newswire)
 
Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today......
26.03.26 - 13:33
 Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer (PR Newswire)
 
Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and......
25.03.26 - 13:33
 Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 (PR Newswire)
 
IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer......
24.03.26 - 13:33
 Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month (PR Newswire)
 
Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patients IRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine......
20.03.26 - 13:33
 Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients (PR Newswire)
 
Highlighting the critical role of Caris GPSai in improving cancer care IRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open,......
16.03.26 - 13:33
 Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer (PR Newswire)
 
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the......
11.03.26 - 13:33
 Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting (PR Newswire)
 
IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five......
09.03.26 - 13:33
 Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer (PR Newswire)
 
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch......
27.02.26 - 17:42
 Caris Life Sciences targets 23–26% revenue growth and $1B milestone in 2026 while expanding early detection investments (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.26 - 00:03
 Caris Life Sciences Completes Interim Readout of Achieve 1 Study (PR Newswire)
 
Demonstrates Superior Sensitivity and Specificity of Caris Detect Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric,......
26.02.26 - 22:51
 Caris Life Sciences, Inc. GAAP EPS of $0.28 beats by $0.18, revenue of $292.2M beats by $11.3M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.02.26 - 22:06
 Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (PR Newswire)
 
Full year revenue growth of 97% driven by strong performance in molecular profiling services Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient......
24.02.26 - 14:33
 Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients′ Oral Chemotherapy Drug (PR Newswire)
 
IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris......
23.02.26 - 14:33
 Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference (PR Newswire)
 
IRVING, Texas, Feb. 23, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference, which will......
09.02.26 - 14:33
 Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26 (PR Newswire)
 
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.......
28.01.26 - 14:33
 Caris Life Sciences′ Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan (PR Newswire)
 
IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab......
12.01.26 - 14:51
 Caris Life Sciences sees Q4 total revenue of about $281M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.01.26 - 14:33
 Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results (PR Newswire)
 
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today......
05.01.26 - 14:33
 Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, which will be......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!